XBI241227P94500
- 3.35
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
SPDR S&P Biotech ETF Declares Quarterly Distribution of $0.0027
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
SPDR S&P Biotech ETF To Go Ex-Dividend On December 23rd, 2024 With 0.00269 USD Dividend Per Share
December 20th (Eastern Time) - $SPDR S&P Biotech ETF(XBI.US)$ is trading ex-dividend on December 23rd, 2024.Shareholders of record on December 23rd, 2024 will receive 0.00269 USD dividend per share
Sarepta Awarded $115.2M in Vyondys 53 Patent Case: Report
Needham Reiterates Hold on Neurocrine Biosciencesto Hold
Neurocrine Biosciences Analyst Ratings
Gilead Sciences Acquires 7.85M Xilio Therapeutics Shares At $1.04 Each, Raising Ownership To Over 10%, Along With 6.1M Pre-Funded Warrants Capped At 19.99% Ownership
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
(GILD) - Analyzing Gilead Sciences's Short Interest
25 U.S. 'Highest Conviction' Stocks – UBS
Gilead Raises Assembly Bio Stake to ~30%
AbbVie's Atogepant And OnabotulinumtoxinA Receive Strong Recommendations In The Newly Updated Canadian Headache Society Migraine Prevention Guideline; A Strong Recommendation Was Issued When An Intervention Was Deemed Suitable For The Majority Of...
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target
Sarepta Therapeutics Analyst Ratings
20 ETFs Primed For Unusually Big Swings On Fed Meeting Days
Incyte Analyst Ratings